Erasca Faces Class Action Lawsuit Over Patent and Clinical Data Claims

The lawsuit, filed in the U.S. District Court for the Southern District of California as Cheng v. Erasca, Inc., centers on accusations that company executives violated the Securities Exchange Act of 1934. According to the complaint, Erasca misrepresented the validity of preclinical data for ERAS-0015, a pan-RAS molecular glue, by utilizing improper comparisons to products developed by Revolution Medicines, Inc. These practices allegedly exposed Erasca to significant patent infringement and trade secret misappropriation risks.

The company’s market valuation faced sharp volatility following disclosures in late April 2026. After receiving notice of patent infringement claims from Revolution Medicines, Erasca shares dropped nearly 11%. The decline deepened by more than 48% after the company revealed preliminary Phase I data, which included the death of a patient and an admission that previous performance comparisons were not derived from head-to-head clinical trials. Investors interested in participating in the action or seeking further information may contact Robbins Geller Rudman & Dowd LLP attorneys Ken Dolitsky or Michael Albert.